Jade Biosciences Inc expected to post a loss of 64 cents a share - Earnings Preview

Jade Biosciences

07/08/2026 15:52

Jade Biosciences Inc JBIO.OQ JBIO.O is expected to  show no change in quarterly revenue when it reports  results on August 11 (estimated) for the period ending June 30 2026

​LSEG's mean analyst estimate for Jade Biosciences Inc is for a loss of 64 cents per share. 
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 11 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Jade Biosciences Inc is $45.00, about 102.3% above its last closing price of $22.24
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-0.48
-0.48
-0.57
Missed
-18.1
Dec. 31 2026
-0.47
-0.48
-0.59
Missed
-24.4
Sep. 30 2025
-0.86
-0.67
-0.48
Beat
28.8​
Jun. 30 2025
-0.48
-0.43
-0.86
Missed
-98.7
​​Mar. 31 2025
-4.55
-8.40
-3.15
Beat
62.5
Dec. 31 2024
-6.65
-8.75
-6.65
Beat
24​
Sep. 30 2024
-21.70
-20.39
-19.60
Beat
3.9
Jun. 30 2024
-28.65
-28.77
-30.10
Missed
-4.6
This summary was machine generated August 7 at 14:52 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)